Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Narkwichean, Amarin; Maalouf, Walid; Campbell, Bruce K; Jayaprakasan, Kannamannadiar (2013)
Publisher: BioMed Central
Journal: Reproductive Biology and Endocrinology : RB&E
Languages: English
Types: Article
Subjects: In vitro fertilization (IVF), Diminished ovarian reserve (DOR), Developmental Biology, Review, Poor ovarian response, Reproductive Medicine, Dehydroepiandrosterone (DHEA), Endocrinology

Classified by OpenAIRE into

mesheuropmc: hormones, hormone substitutes, and hormone antagonists, endocrine system
Women with diminished ovarian reserve often respond poorly to controlled ovarian stimulation resulting in retrieval of fewer oocytes and reduced pregnancy rates. It has been proposed that pre-IVF Dehydroepiandrosterone (DHEA) adjuvant therapy may improve ovarian response and pregnancy rates in women with diminished ovarian reserve. This meta-analysis aims to investigate efficacy of DHEA as an adjuvant to improve ovarian response and IVF outcome in women with diminished ovarian reserve. Electronic databases were searched under the following terms: (DHEA) and (diminished ovarian reserve) and/or (poor response). Studies were included if they reported at least one of the following outcomes; clinical pregnancy rate, number of oocytes retrieved, miscarriage rate. We identified 22 publications determining effects of DHEA in clinical trials. Only 3 controlled studies were eligible for meta-analysis. There was no significant difference in the clinical pregnancy rate and miscarriage rates between women pre-treated with DHEA compared to those without DHEA pre-treatment (RR 1.87, 95% CI 0.96-3.64; and RR 0.59, 95% CI 0.21-1.65, respectively). The number of oocytes retrieved (WMD -1.88, 95% CI -2.08, 1.67; P < 0.001) was significantly lower in the DHEA group. In conclusion, based on the limited available evidence from a total of approximately 200 IVF cycles, there are insufficient data to support a beneficial role of DHEA as an adjuvant to controlled ovarian stimulation in IVF cycle. Well-designed, randomised controlled trials as well as more exact knowledge about DHEA mechanisms of action are needed to support use of DHEA in standard practice for poor-responders.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Menken J, Trussell J, Larsen U: Age and infertility. Science 1986, 233:1389-1394.
    • 2. Templeton A, Morris JK, Parslow W: Factors that affect outcome of in-vitro fertilisation treatment. Lancet 1996, 348:1402-1406.
    • 3. Trout SW, Seifer DB: Do women with unexplained recurrent pregnancy loss have higher day 3 serum FSH and estradiol values? Fertil Steril 2000, 74:335-337.
    • 4. Freeman SB, Yang Q, Allran K, Taft LF, Sherman SL: Women with a reduced ovarian complement may have an increased risk for a child with Down syndrome. Am J Hum Genet 2000, 66:1680-1683.
    • 5. Keay SD, Liversedge NH, Mathur RS, Jenkins JM: Assisted conception following poor ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecol 1997, 104:521-527.
    • 6. Leong M, Patrizio P: Poor responders: how to define, diagnose and treat? 2010. http://www.ivf-worldwide.com/survey/poor-responders/results-poorresponders.html.
    • 7. Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S: Interventions for 'poor responders' to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev 2010, 20, CD004379.
    • 8. Casson PR, Lindsay MS, Pisarska MD, Carson SA, Buster JE: Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: a case series. Hum Reprod 2000, 15:2129-2132.
    • 9. Wiser A, Gonen O, Ghetler Y, Shavit T, Berkovitz A, Shulman A: Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod 2010, 25:2496-2500.
    • 10. Hillier SG, Tetsuka M: Role of androgens in follicle maturation and atresia. Baillieres Clin Obstet Gynaecol 1997, 11:249-260.
    • 11. Walters KA, Simanainen U, Handelsman DJ: Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models. Hum Reprod Update 2010, 16:543-558.
    • 12. Barad D, Gleicher N: Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 2006, 21:2845-2849.
    • 13. Nielsen ME, Rasmussen IA, Kristensen SG, Christensen ST, Møllgård K, Wreford Andersen E, Byskov AG, Yding Andersen C: In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Mol Hum Reprod 2011, 17:63-70.
    • 14. Walters KA, Allan CM, Handelsman DJ: Androgen actions and the ovary. Biol Reprod 2008, 78:380-389.
    • 15. Menezo Y, Dale B, Cohen M: DNA damage and repair in human oocytes and embryos: a review. Zygote 2010, 18:357-365.
    • 16. Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes FJ: Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005, 28:1636-1642.
    • 17. Sunkara SK, Pundir J, Khalaf Y: Effect of androgen supplementation or modulation on ovarian stimulation outcome in poor responders: a metaanalysis. Reprod Biomed Online 2011, 22:545-555.
    • 18. Wells GA, Shea B, O'connell D, Peterson J, Welch V, Losos MPT: The Newcastle-Ottawa Scale (NOS) for assessing thequality if nonrandomized studies in meta-analyses. Ottawa; 2004. http://www.ohri.ca/programs/ clinical_epidemiology/oxford.asp.
    • 19. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
    • 20. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
    • 21. Barad DH, Gleicher N: Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril 2005, 84:756.
    • 22. Mamas L, Mamas E: Dehydroepiandrosterone supplementation in assisted reproduction: rationale and results. Curr Opin Obstet Gynecol 2009, 21:306-308.
    • 23. Sönmezer M, Cil AP, Oktay K: Ongoing pregnancies from early retrieval of prematurely developing antral follicles after DHEA supplementation. Reprod Biomed Online 2009, 19:816-819.
    • 24. Gleicher N, Weghofer A, Barad DH: Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS). Reprod Biol Endocrinol 2010, 8:140.
    • 25. Barad D, Brill H, Gleicher N: Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet 2007, 24:629-634.
    • 26. Gleicher N, Ryan E, Weghofer A, Blanco-Mejia S, Barad DH: Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod Biol Endocrinol 2009, 7:108.
    • 27. Gleicher N, Weghofer A, Barad DH: Improvement in diminished ovarian reserve after dehydroepiandrosterone supplementation. Reprod Biomed Online 2010, 21:360-365.
    • 28. Sönmezer M, Ozmen B, Cil AP, Ozkavukçu S, Taşçi T, Olmuş H, Atabekoğlu CS: Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders. Reprod Biomed Online 2009, 19:508-513.
    • 29. Weissman A, Horowitz E, Ravhon A, Golan A, Levran D: Dehydroepiandrosterone supplementation increases baseline follicular phase progesterone levels. Gynecol Endocrinol 2011, 27:1014-1017.
    • 30. Hyman JH, Margalioth EJ, Rabinowitz R, Tsafrir A, Gal M, Alerhand S, Algur N, Eldar-Geva T: DHEA supplementation may improve IVF outcome in poor responders: a proposed mechanism. Eur J Obstet Gynecol Reprod Biol 2013, 168:49-53.
    • 31. Gleicher N, Kim A, Weghofer A, Shohat-Tal A, Lazzaroni E, Lee HJ, Barad DH: Starting and resulting testosterone levels after androgen supplementation determine at all ages in vitro fertilization (IVF) pregnancy rates in women with diminished ovarian reserve (DOR). J Assist Reprod Genet 2013, 30:49-62.
    • 32. Hyman JH, Margalioth EJ, Rabinowitz R, Tsafrir A, Algur N, Eldar-Geva T: Dehydroepiandrosterone (DHEA) supplementation for poor responders - How does it work? Fertil Steril 2010, 94:S86.
    • 33. Gleicher N, Goyal A, Weghofer A, Barad D: Supplementation with dehydroepiandrosterone (DHEA) improves ovarian reserve, as reflected by anti-mullerian hormone levels. Fertil Steril 2009, 92:S54-S55.
    • 34. Goyal A, Barad D, Weghofer A, Oktay K, Gleicher N: Predicting improvements in ovarian reserve and pregnancy rates after supplementation of dehydroepiandrosterone (DHEA) in diminished ovarian reserve. Hum Reprod 2009, 24:i79.
    • 35. Gleicher N, Barad DH: Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol 2011, 9:67.
    • 36. Yakin K, Urman B: DHEA as a miracle drug in the treatment of poor responders; hype or hope? Hum Reprod 2011, 26:1941-1944.
    • 37. Urman B, Yakin K: Does dehydroepiandrosterone have any benefit in fertility treatment? Curr Opin Obstet Gynecol 2012, 24:132-135.
    • 38. Sunkara SK, Coomarasamy A, Arlt W, Bhattacharya S: Should androgen supplementation be used for poor ovarian response in IVF? Hum Reprod 2012, 27:637-640.
    • 39. Kolibianakis EM, Venetis CA, Tarlatzis BC: DHEA administration in poor responders. Hum Reprod 2011, 26:730-731. author reply 731.
    • 40. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L: Definition EwgoPOR: ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011, 26:1616-1624.
    • 41. Broekmans FJ, Soules MR, Fauser BC: Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009, 30:465-493.
    • 42. Bosdou JK, Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Zepiridis L, Tarlatzis BC: The use of androgens or androgen-modulating agents in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update 2012, 18:127-145.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article